Skip To Main Content
Lizette Borreli on Muck Rack

Lizette Borreli

Verified
New York
As seen in: Medscape, MSN, MSN India, Newsweek, Flipboard, International Business Times (U.S.), Emergency Medicine News, Medscape France, Medscape Noticias Médicas, Neurology Today, The Nurse Practitioner and
Managing Editor @NeuroAdvisor | Formerly @TheHealthy @NeurologyToday @BrainandLifeMag @Newsweek | @Hunter_College | Sports Enthusiast | Outdoorsy | Bilingual
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lizette

Contact Lizette, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Lizette Borreli’s Biography

Read Full Bio →

Liz Borreli is a writer, a film critic and a sports enthusiast. She received her BA in Media Studies from CUNY Hunter College, where she wrote for two school papers, The Hunter Word and The Envoy. Liz has also contributed to the neighborhood paper the Greenpoint Gazette covering local issues in Greenpoint and Williamsburg, Brooklyn. Her coverage of recent film festivals include the Sprout Film Festival, the New York Film Festival and the Tribeca Film Festival.

Articles

Surprising Signal for Semaglutide in Bipolar Disorder

|
By Lizette Borreli Verified
| Medscape Verified
The GLP-1 semaglutide is associated with a lower risk for psychiatric hospitalization and relapse in patients with bipolar disorder (BD) and diabetes and/or obesity. In a large observational study, semaglutide was associated with a 21% lower risk for psychiatric hospitalization and a 17% lower risk for hospitalization for BD relapse.
Open in Who Shared Issue with article?

Antiseizure Med Linked to a Twofold Increased Thromboembolic Risk With DOACs

|
By Lizette Borreli Verified
| Medscape Verified
Levetiracetam, a widely used antiseizure medication (ASM) often favored for its low potential for drug interactions, may warrant greater caution when prescribed with direct oral anticoagulants (DOACs), after new observational data linked the combination to a nearly twofold higher risk for thromboembolic events.
Open in Who Shared Issue with article?

APOE epsilon 4 Flags Lecanemab-related ARIA Risk but Falls Short as a Predictor

|
By Lizette Borreli Verified
| Medscape Verified
A known genetic risk factor for amyloid-related imaging abnormalities (ARIA) associated with the antiamyloid lecanemab may offer little help in predicting who will actually develop the potentially serious complication, new real-world data suggest. APOE epsilon 4 was associated with a greater likelihood of ARIA — particularly among homozygous carriers — but it did not reliably identify who would go on to develop the complication.
Open in Who Shared Issue with article?
See all 1,267 licensed articles (1,292 Total)